JP2008516991A5 - - Google Patents

Download PDF

Info

Publication number
JP2008516991A5
JP2008516991A5 JP2007537071A JP2007537071A JP2008516991A5 JP 2008516991 A5 JP2008516991 A5 JP 2008516991A5 JP 2007537071 A JP2007537071 A JP 2007537071A JP 2007537071 A JP2007537071 A JP 2007537071A JP 2008516991 A5 JP2008516991 A5 JP 2008516991A5
Authority
JP
Japan
Prior art keywords
use according
antisense compound
administered
animal
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007537071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2005/001634 external-priority patent/WO2006086821A1/en
Publication of JP2008516991A publication Critical patent/JP2008516991A/ja
Publication of JP2008516991A5 publication Critical patent/JP2008516991A5/ja
Pending legal-status Critical Current

Links

JP2007537071A 2004-10-20 2005-10-20 インテグリンα４発現のアンチセンス調節 Pending JP2008516991A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62079204P 2004-10-20 2004-10-20
US64882005P 2005-01-31 2005-01-31
PCT/AU2005/001634 WO2006086821A1 (en) 2004-10-20 2005-10-20 ANTISENS MODULATION OF INTEGRIN α4 EXPRESSION

Publications (2)

Publication Number Publication Date
JP2008516991A JP2008516991A (ja) 2008-05-22
JP2008516991A5 true JP2008516991A5 (enExample) 2008-12-04

Family

ID=36916094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537071A Pending JP2008516991A (ja) 2004-10-20 2005-10-20 インテグリンα４発現のアンチセンス調節

Country Status (9)

Country Link
US (1) US8765700B2 (enExample)
EP (1) EP1809302B1 (enExample)
JP (1) JP2008516991A (enExample)
AU (1) AU2005327506B2 (enExample)
CA (1) CA2584614A1 (enExample)
DK (1) DK1809302T3 (enExample)
ES (1) ES2392449T3 (enExample)
NZ (1) NZ554277A (enExample)
WO (1) WO2006086821A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008474A2 (en) * 2008-06-23 2010-01-21 Teva Pharmaceutical Industries, Ltd. Methods for treating multiple sclerosis using antisense oligonucleotides
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20130323196A1 (en) * 2010-09-17 2013-12-05 Antisense Thereapeutics Ltd Method for mobilizing stem and/or progenitor cells
WO2013142514A1 (en) * 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
WO2013180736A1 (en) * 2012-06-01 2013-12-05 Intel Corporation Identification and execution of subsets of a plurality of instructions in a more secure execution environment
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
AU2016259971B2 (en) * 2015-05-11 2021-12-09 ProGenis Pty Ltd Multiple sclerosis treatment
WO2017075670A1 (en) * 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
MX2019008252A (es) 2017-01-10 2019-09-06 Arrowhead Pharmaceuticals Inc Agentes de interferencia de acido ribonucleico (iarn) de alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y metodos de uso.
EP3787639A4 (en) 2018-05-04 2022-02-23 Antisense Therapeutics Ltd THERAPEUTIC USES AND PROCESSES
WO2020247774A1 (en) * 2019-06-06 2020-12-10 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
WO2023039643A1 (en) * 2021-09-20 2023-03-23 Antisense Therapeutics Ltd Methods and kits therefor
TW202525305A (zh) * 2022-11-09 2025-07-01 香港商Ｇｍｐ生物技術有限公司 用於cns疾病的組成物及方法
AU2023375420A1 (en) * 2022-11-09 2025-06-19 Gmp Biotechnology Limited Anti-cancer agents

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
EP0497875B1 (en) 1989-10-24 2000-03-22 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5955589A (en) 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (de) 1990-05-11 1998-11-26 Microprobe Corp., Bothell, Wash. Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden
ES2103918T3 (es) 1991-10-17 1997-10-01 Ciba Geigy Ag Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
AU6449394A (en) 1993-03-30 1994-10-24 Sterling Winthrop Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
PT733059E (pt) 1993-12-09 2001-03-30 Univ Jefferson Compostos e metodos para mutacoes dirigidas ao local em celulas eucarioticas
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5696248A (en) 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6083923A (en) 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
DE19860642A1 (de) * 1998-12-29 2000-07-06 Deutsches Krebsforsch Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen
IL140054A0 (en) * 1999-04-06 2002-02-10 Univ East Carolina Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
AU2006216514C1 (en) * 2005-02-25 2012-09-27 Isis Pharmaceuticals, Inc. Compositions and their uses directed to IL-4R alpha

Similar Documents

Publication Publication Date Title
JP2008516991A5 (enExample)
KR100414699B1 (ko) 폐병치료에유용한디뉴클레오티드
Dhand et al. How best to deliver aerosol medications to mechanically ventilated patients
AU2002351181B2 (en) Methods and compositions for treating lesions of the respiratory epithelium
JP2009529539A (ja) 呼吸器障害を治療するための方法および組成物
JP2010508365A5 (enExample)
US20090227511A1 (en) Methods and compositions for treating lesions of the respiratory epithelium
JP2025185070A5 (enExample)
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
WO1998023294A1 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
JP2012505262A (ja) Ｃｏｐｄ及びその他の肺疾患の治療方法
WO2005063777A8 (en) Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
JP2024071397A5 (enExample)
WO1998023294A9 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
JP2020526192A5 (enExample)
Siobal Aerosolized prostacyclins
JP2013522295A5 (enExample)
Everard et al. In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system.
RU2008102655A (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
JP2009506029A5 (enExample)
JP2008543926A5 (enExample)
JPWO2022216920A5 (enExample)
Ceriana et al. Use of bronchodilators during non-invasive mechanical ventilation